Make Informed Investment Decisions with Affordable Access to Experts

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

HBV-23 vs GSK's Engerix-B. How good was the recent data and how big a vaccine can HBV-23 really be?

Ticker(s): DVAX, GSK

Who's the expert?

Name: Dr Ashwin Balagopal - MD

Institution: Johns Hopkins University

Bio:

  • Assistant professor of Medicine and Infectious Disease
  • Research interests include microbial translocation and Kupffer cells in HIV-HCV coinfection and in situ liver studies of HIV-HCV pathogenesis.
  • Member of several professional organizations and authored a number of publications in peer reviewed journal

Interview Questions
Q1.

Please give us a little information about your background in Hep-B.

Added By: joe_mccann
Q2.

Can you give us an idea of the Hep-B vaccine market now, what types of patients get vaccinated and how well covered people are currently?

Added By: joe_mccann
Q3.

What is you initial impression to the top line data released by Dynavax?

Added By: joe_mccann
Q4.

Do you see the data for HBV-23 being compelling enough that you would switch from using Engerix-B to HBV-23 if it was approved?

Added By: joe_mccann
Q5.

Is Bells Palsy a side effect associated with current adult hepatitis B vaccines (Engerix)? How would a two dose regimen over 4 weeks impact compliance versus a three dose regimen over 6 months in the typical target patient in your opinion?

Added By: sea4pines
Q6.

What is the current standard of care for high risk populations, like diabetics, elderly and obese patients? How do you see HBV-23 changing this paradigm? 

Added By: neuman101
Q7.

What can you tell us about compliance among diabetics since ACIP's recommendation re: hep b vaccination four years ago? If low, is this an education issue? Compliance issue? Other?

Added By: kingsly
Q8.

How would you view a premium price for HBV-23, considering the potential compliance improvements? 

Added By: kingsly
Q9.

How much would a two dose regimen over one month improve compliance vs. the three dose regimen over 6 months in your opinion

Added By: sea4pines

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.